In patients with acute central retinal vein occlusion, a history of systemic hypertension and presenting with worse visual acuity and a relative afferent pupillary defect predict the development of neovascular glaucoma, a retrospective study has shown.
A new study from the UK has suggested that patients recently diagnosed with ocular hypertension or open angle glaucoma (OAG) could derive greater benefit from undergoing selective laser trabeculoplasty (SLT) rather than being treated with intraocular pressure-reducing eye drops.
A UK study has recently found that while adalimumab is clinically effective in uveitis associated with juvenile idiopathic arthritis (JIA), its cost-effectiveness compared with methotrexate alone in the UK setting is not demonstrated.
Higher adherence to the Mediterranean Diet (MedDiet) results in a 41-percent reduced risk of incident advanced age-related macular degeneration (AMD), according to pooled data from the Rotterdam Study I (RS-I) and Alienor* Study.
New drug applications approved by US FDA as of 01 - 15 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Long-term monotherapy with intravitreal aflibercept (IAI) is noninferior to IAI with rescue photodynamic therapy (IAI + rPDT) in terms of functional and anatomical improvements in patients with polyploidal choroidal vasculopathy (PCV), a new Singapore analysis of the PLANET* study has found.
drug applications approved by US FDA as of 16 - 28 February 2019 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.
Retinal microvascular signs, while relatively rare, may reflect microvascular pathology in the brain, which potentially leads to dementia and cognitive impairment, according to a recent cross-sectional analysis of the Atherosclerosis Risk in Communities cohort.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.